Half Report Severe Side Effects From Breast Cancer Therapy

TUESDAY, Jan. 24, 2017 -- About half of early stage breast cancer patients experience severe side effects from their treatment, a new study finds. " It's in patients'best interest to receive their treatments on time and on schedule, whenever...
Source: Drugs.com - Daily MedNews - Category: Journals (General) Source Type: news

Related Links:

AbstractPurpose of ReviewThere are competing risks and benefits of cancer therapies and fertility preservation in young women with breast cancer. Here we discuss the impact of therapy on fertility, fertility preservation options, and emerging information in fertility issues for the breast cancer patient.Recent FindingsAll systemic forms of breast cancer treatment can impact future fertility. Pre-therapy fertility preservation may offer the best opportunity for future fertility. Shared decision making with the individual patient and clinical scenario is important. Early referral to a fertility specialist should be offered t...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Bone health is an important consideration in patients with solid tumours, as both metastasis to bone and cancer therapy-induced bone loss (CTIBL) can increase morbidity and reduce quality of life [1,2]. Bone is a common site of metastasis in patients with cancer, with prostate, breast and lung the most frequent tumours leading to bone metastasis, accounting for 34%, 22% and 20% of cases, respectively [3]. A recent study in patients with solid tumours in the USA estimated the incidence of bone metastases in patients with solid tumours to be 6.9% at 5 years after diagnosis and 8.4% at 10 years [4], while a meta-analysis of 1...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: General and Supportive Care Source Type: research
ConclusionsIn this era of increasing choices of MBC therapeutic agents and no superior approach to choosing a treatment regimen, the ability to compare multiple therapies based on survival, toxicity and cost would enable treating physicians to optimize therapeutic choices for patients. For investigators, it can point them in research directions that were previously non-obvious and for guideline designers, enable them to efficiently review the MBC clinical trial literature and visualize how regimens compare in the key dimensions of clinical benefit, toxicity, and cost.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Abstract Autophagy is an evolutionary conserved, self-eating process that targets cellular constituents for lysosomal degradation. Transcription factor EB (TFEB) is a master regulator of autophagy by inducing the expression of genes involved in autophagic and lysosomal degradation. In breast cancer, ligand-activated progesterone receptor has been reported to influence cancer development by manipulating the autophagy pathway. However, understanding of the mechanism that underlies the autophagic response remains limited. Herein, we report that prolonged treatment with progestin R5020 upregulates autophagy in MCF-7 h...
Source: Experimental Cell Research - Category: Cytology Authors: Tags: Exp Cell Res Source Type: research
ösch S Abstract The G protein-coupled estrogen receptor 1 (GPER1) is involved in the regulation of physiological processes such as cellular growth and proliferation, but also in pathophysiological processes such as tumor development. The role of GPER1 in breast cancer is contradictory. Therefore, we investigated the influence of GPER1 overexpression on cellular processes in MCF-7 breast cancer cells. GPER1 overexpression leads to a cell cycle arrest in the G1 phase, induction of autophagy and reduced proliferation. Reduced proliferation was accompanied by a reduced basal respiration and reduced glycolysis rat...
Source: The International Journal of Biochemistry and Cell Biology - Category: Biochemistry Authors: Tags: Int J Biochem Cell Biol Source Type: research
Abstract Signal transducer and activator of transcription 3 (STAT3) is a latent transcription factor that contributes to tumor cell growth and survival and is often constitutively active in several types of cancers, which makes it an attractive target for cancer therapy. We identified 5,5'-(pentane-1,5'-diyl)bis(2-methyl-1,4-benzoquinone) (BPMB) as a new STAT3 inhibitor. BPMB inhibited the transcriptional activities of STAT3, despite its inability to reduce the phosphorylation and nuclear translocation of STAT3. BPMB selectively inhibited the proliferation of human breast cancer cell lines with constitutively acti...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
In conclusion, an efficient liposomal delivery system for the combination of miRNA and siRNA to target the BCSCs was developed and could be used as an efficacious therapeutic modality for breast cancer.Graphical AbstractHerceptin-conjugated cationic liposome can enhance the cellular uptake of let-7 miRNA and CDK4 siRNA toward the HER-2 expressing breast cancer stem cells.
Source: Asian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
We reported that Caco-2 cancer cells are more sensitive than HCT 116 cancer cells to nano-DOX and nano-Se. Nano-DOX plus nano-Se induces cytotoxicity-mediated late apoptosis in Caco-2 more than HCT 116 cell lines. This de novo strategy could have great power to overcome the problem of DOX resistance during colon cancer therapy. PMID: 31066020 [PubMed - as supplied by publisher]
Source: Biological Trace Element Research - Category: Biology Authors: Tags: Biol Trace Elem Res Source Type: research
la CM Abstract Cardiac monitoring is becoming an important part of breast cancer care. Breast cancer and cardiovascular disease (CVD) share many common risk factors, and it is estimated that by the median age of diagnosis, many patients with breast cancer will have established or subclinical CVD. In addition, a number of treatments for metastatic breast cancer are known to have cardiac effects. As such, there is a clear need to prevent, identify, and effectively manage cardiovascular events in patients with breast cancer. Current clinical practice for patients with metastatic breast cancer involves a comprehensive...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence. Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers. The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack. The Lumicell System already has been studi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | General Medicine | Study